A Phase 4 interventional study of Risperidone in Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder, sponsored by Janssen-Cilag Ltd.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-14.
Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.
Among the 127 studies testing risperidone in Schizophrenia, this one is the 78th largest by enrollment of the 123 interventional ones that give a count, is one of 7 that started in 2007, is one of 63 in phase 4, and was the 85th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 7 · Phase 3 34 · Phase 4 63
First in 1996; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 123 interventional studies. Of the 106 that completed or were terminated, 30 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Ltd. is the lead sponsor of 35 studies on the registry; 4 are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 113th largest by enrollment of the 176 interventional ones that give a count, is one of 24 that started in 2007, is one of 47 in phase 4, and was the 176th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing risperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 127 studies testing risperidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), schizophreniform or schizoaffective disorders (disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations).
This is an open-label (all people know the identity of the intervention), longitudinal (participants are followed over time with continuous or repeated monitoring of risk factors or health-outcomes), non-randomized (a clinical trial in which the participants are not assigned by chance to different treatment groups), single-center study to evaluate the efficacy and safety of long acting microspheres of risperidone in adult participants with schizophrenia, schizophreniform or schizoaffective disorders. The duration of this study will be 12 months and duration of treatment will be 6 months. The study will include 4 visits: Baseline, and 3 follow-up visits including Week 4, 12 and 26. All eligible participants will be treated with risperidone 25 milligram (mg) intramuscular injection (injection of a substance into a muscle) for every two weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics (agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect) will be initiated with higher doses of risperidone. Doses will be adjusted according to the response of the treatment. Efficacy and safety of the participants will be primarily evaluated by Positive and Negative Syndromes Scale (PANSS) and Extrapyramidal Symptom Rating Scale (ESRS), respectively. Participants' quality of life and safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
Drug: Risperidone
Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening. Change at Week 26 score is calculated as Baseline score minus Week 26 score.
Time frame: Baseline and Week 26
Clinical Global Impressions (CGI) - Disease Severity Score
The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.
Time frame: Baseline and Week 26
Short Form-36 (SF-36) - Quality of Life Score
The SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: vitality, physical function, social function, physical role, emotional role, bodily pain, general health, mental health. Each item is scored on a scale ranging from 0-100 (100=highest level of functioning).
Time frame: Baseline and Week 26
Global Assessment of Functioning (GAF) Score
The GAF is a 100-point tool to measure overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.
Time frame: Baseline and Week 26
Patient Satisfaction With Treatment
Participants' were assessed for their satisfaction with the current antipsychotic treatment on a 5-point scale/questionnaire: very good, good, reasonable, moderate or poor.
Time frame: Baseline and Week 26
Extrapyramidal Symptom Rating Scale (ESRS) Score
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, absent) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.
Time frame: Baseline and Week 26
| Milestone | Risperidone |
|---|---|
| Started | 80 |
| Treated | 79 |
| Completed | 66 |
| Not completed | 14 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Started but not treated | 1 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening. Change at Week 26 score is calculated as Baseline score minus Week 26 score.
| Units on a scale | Risperidone |
|---|---|
| Baseline (n=78) | 68.9 ± 15.8 |
| Change at Week 26 (n=66) | 28.1 ± 17.1 |
The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.
| Units on a scale | Risperidone |
|---|---|
| Baseline (n=78) | 4.2 ± 4.0 |
| Week 26 (n=66) | 2.9 ± 3.0 |
The SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: vitality, physical function, social function, physical role, emotional role, bodily pain, general health, mental health. Each item is scored on a scale ranging from 0-100 (100=highest level of functioning).
| Units on a scale | Risperidone |
|---|---|
| Baseline; Physical function (n=78) | 78.3 ± 21.7 |
| Week 26; Physical function (n=66) | 90.5 ± 13.8 |
| Baseline; Physical role (n=78) | 41.0 ± 46.5 |
| Week 26; Physical role (n=66) | 75.4 ± 41.0 |
| Baseline; Body pain (n=78) | 86.2 ± 19.8 |
| Week 26; Body pain (n=66) | 94.7 ± 11.8 |
| Baseline; General health (n=78) | 51.7 ± 18.3 |
| Week 26; General health (n=66) | 67.8 ± 12.0 |
| Baseline; Vitality (n=78) | 51.7 ± 16.8 |
| Week 26; Vitality (n=66) | 58.6 ± 11.5 |
| Baseline; Social function (n=78) | 49.0 ± 20.4 |
| Week 26; Social function (n=66) | 74.1 ± 18.1 |
| Baseline; Emotional role (n=78) | 32.1 ± 46.0 |
| Week 26; Emotional role (n=66) | 73.2 ± 42.3 |
| Baseline; Mental health (n=78) | 50.7 ± 13.8 |
| Week 26; Mental health (n=66) | 59.9 ± 12.8 |
The GAF is a 100-point tool to measure overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.
| Units on a scale | Risperidone |
|---|---|
| Baseline (n=78) | 56.5 ± 14.2 |
| Week 26 (n=66) | 69.4 ± 11.7 |
Participants' were assessed for their satisfaction with the current antipsychotic treatment on a 5-point scale/questionnaire: very good, good, reasonable, moderate or poor.
| Participants | Risperidone |
|---|---|
| Baseline; Very good (n=78) | 2 |
| Week 26; Very good (n=66) | 16 |
| Baseline; Good (n=78) | 13 |
| Week 26; Good (n=66) | 40 |
| Baseline; Moderate (n=78) | 42 |
| Week 26; Moderate (n=66) | 10 |
| Baseline; Poor (n=78) | 19 |
| Baseline; Very poor (n=78) | 1 |
| Baseline; No available (n=78) | 1 |
An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, absent) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.
| Units on a scale | Risperidone |
|---|---|
| Baseline | 12.9 ± 9.6 |
| Week 26 | 9.2 ± 5.1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risperidone | — | 1/79 (1.3%) | 1/79 (1.3%) |
| Event | Risperidone |
|---|---|
| Psychotic disorderPsychiatric disorders | 1/79 |
| Event | Risperidone |
|---|---|
| Extrapyramidal disorderNervous system disorders | 1/79 |
| Age Continuous(Years) | Risperidone |
|---|---|
| Mean | 43.0 ± 12.4 |
| Sex: Female, Male(Participants) | Risperidone |
|---|---|
| Female | 32 |
| Male | 47 |
No study locations are listed for this record.
The record gives a start of Nov 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risperidone